New migraine drugs

Puledda, Francesca; Tassorelli, Cristina; Diener, Hans-Christoph

doi:10.1177/03331024221144784

Cited by 3 publications

(2 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Puledda F et al [ 12 , 13 ] present aspects of up-to-date therapeutic agents for the treatment of migraine, including molecules targeting CGRP, serotonin 5-HT 1F receptor agonists and non-invasive neuromodulation, as options for both acute and preventive treatment.…”

Section: Introductionmentioning

confidence: 99%

Neurasites®—A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks

Lunguț,

Antal,

Turcu

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Migraine is one of the most common diseases in highly developed countries, being even more common than diabetes and asthma. Migraines can affect emotional, social, and physical wellbeing as well as professional life. The most common symptoms are severe headaches associated with nausea, vomiting, photophobia and sonophobia, difficulty concentrating, sensitivity and emotional disorders. Many studies have been published to establish the best migraine-management drugs, but not many of them refer to plant extracts, which have been given more attention by patients lately. Among these generically called herbal medicines, the effect of tussilago hybrida standardized extract has been studied since the early twenties. This stands as the fundamental component of Neurasites® and the reason for research on materials and methods, results on treatment schemes for diminishing migraine attack features, as well as migraine prevention. Methods: There are two directions of research (herbal and placebo medicine) considered to be of interest due to the actual trend toward natural medicine and against chemicals and associated drugs. For quantitative research, the research tool used was that of the Neurasites® Questionnaire Survey (NQS). Results: The obtained results prove the efficacy of treatment by reducing the duration of headache attacks, diminishing pain intensity and decreasing the frequency of migraine episodes. Conclusions: Further research development should focus on other dosages and treatment schemes and on other similar natural products to be used in migraine attack treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Neurasites®—A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks

Lunguț,

Antal,

Turcu

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…The development of ubrogepant has been hailed as a significant step forward in migraine therapeutics [ 23 ]. Unlike triptans, which are contraindicated in people with certain cardiovascular conditions, ubrogepant does not have vasoconstrictive properties, making it a safer option for a broader range of patients [ 23 , 24 ]. Furthermore, early clinical trials have shown that ubrogepant effectively relieves migraine symptoms without the typical side effects associated with other migraine medications [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine

Dighriri,

Nazel,

Alharthi

et al. 2023

Cureus

View full text Add to dashboard Cite

Ubrogepant is an innovative medication designed for the acute treatment of migraine, a debilitating neurological condition that profoundly impairs quality of life, productivity, and social interactions. This comprehensive review assesses the efficacy, safety, tolerability, and mechanism of action of ubrogepant through a rigorous methodology, including an in-depth literature review from reputable databases like PubMed, Web of Science, Embase, Scopus, and Cochrane. Classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, ubrogepant has emerged as a potential revolutionary medication for migraine treatment. CGRP is a peptide integral to migraine pathophysiology, and its blockade has demonstrated great therapeutic potential. Unlike triptans, known for their cardiovascular risks, ubrogepant lacks vasoconstrictive properties, making it a safer alternative for a broader patient population. Ubrogepant offers significant potential for pain relief, symptom reduction, and restoration of normal function during a migraine attack, and it outperforms placebo in terms of efficacy. It also presents favorable safety, with generally mild adverse drug events (ADEs), such as nausea, dizziness, and somnolence, similar to placebo effects. Consistent results from clinical trials confirm its tolerability, with minor ADEs and no safety alerts for the tested doses, indicating that ubrogepant is a safe and well-tolerated option for migraine treatment. As an effective oral medication, ubrogepant could be an alternative to traditional acute migraine treatments. Its benefits include a unique mechanism of action, rapid onset, and favorable safety profile. However, specific contraindications, such as hypersensitivity, severe hepatic impairment, concurrent use of CYP3A4 inhibitors, pregnancy or breastfeeding, and uncontrolled hypertension, require caution or avoidance of ubrogepant. Despite these limitations, ubrogepant signals a promising new direction in migraine therapeutics.

show abstract

Neue Migränetherapeutika im Fokus

Diener

2023

InFo Neurologie

View full text Add to dashboard Cite

New migraine drugs

Cited by 3 publications

References 7 publications

Neurasites®—A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks

Neurasites®—A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine

Neue Migränetherapeutika im Fokus

Contact Info

Product

Resources

About